News from bioarctic A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 15, 2021, 03:20 ET BioArctic and Eisai presented latest data regarding lecanemab at AD/PD 2021

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced data on the drug candidate lecanemab (BAN2401), which were presented by the company...

Mar 05, 2021, 02:21 ET Latest lecanemab data to be presented at the AD/PD™ congress

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data relating...

Feb 03, 2021, 02:26 ET Eisai increases the number of participants in Clarity AD study

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have increased the participant target number by...

Jan 27, 2021, 02:11 ET BioArctic receives European patent for new antibodies targeting Alzheimer's disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent...

Jan 26, 2021, 02:12 ET Invitation to presentation of BioArctic's Full Year Report for the period January - December 2020 on February 4 at 9.30 a.m. CET

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's Full Year Report for the period January - December 2020 on Thursday,...

Nov 09, 2020, 02:09 ET Eisai presented latest data regarding drug candidate BAN2401 at CTAD 2020

BioArctic AB (publ) [Nasdaq Stockholm: BIOA B] announced today data on the drug candidate BAN2401 (lecanemab), which were presented by the company's...

Oct 28, 2020, 04:17 ET BioArctic's partner Eisai to present latest data on BAN2401 at CTAD conference

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company's partner Eisai will conduct four oral presentations related to the...

Oct 15, 2020, 07:24 ET BioArctic winner of the Allbright Award 2020

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has been awarded the 2020 Allbright Award for its focused work with...

Oct 06, 2020, 02:46 ET Invitation to presentation of BioArctic's Interim Report for the period January - September 2020 on October 14 at 9.30 a.m. CET

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company's Interim Report for the period January - September 2020 on Wednesday, October...

Jul 30, 2020, 04:17 ET Eisai presents the latest data from the Phase 2b open-label extension study of BAN2401 at AAIC 2020

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company's partner Eisai presented the latest data from the open-label...

Jul 22, 2020, 02:47 ET BioArctic's Partner Eisai to Present Update on the Development of BAN2401 at Alzheimer's Association International Conference 2020

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company's partner Eisai will present the study design of the Phase 3 program...

Jul 14, 2020, 02:13 ET New Global Phase 3 Program of BAN2401 Initiated in Preclinical (Asymptomatic) Alzheimer's Disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that its business partner Eisai, in collaboration with Alzheimer's Clinical Trials...

Jul 01, 2020, 02:43 ET Invitation to Presentation of BioArctic's Interim Report for the Period January - June 2020 on July 10 at 9.30 a.m. CET

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company's Interim Report for the period January - June 2020 on Friday, July 1, 2020, at ...

Jun 29, 2020, 02:45 ET BioArctic and University of Oslo Sign Research Agreement to Investigate Apolipoprotein E as a Drug Target for Alzheimer's Disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and University of Oslo, Institute of Clinical Medicine (IKM), announced today that they have signed a...

May 26, 2020, 09:48 ET Members of BioArctic's Board of Directors and Management Increase Their Shareholdings

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that seven members of the company's Board and management today have exercised options to...

May 07, 2020, 12:53 ET Report from Annual General Meeting in BioArctic (publ)

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today held its Annual General Meeting. The following resolutions were adopted. Adoption of the income...

Apr 22, 2020, 02:47 ET Interim Report for the period January - March 2020

Operations performing according to plan Key events during the first quarter 2020 As of today, BioArctic has not experienced any noteworthy...

Apr 15, 2020, 02:43 ET Invitation to Presentation of BioArctic's Interim Report for the First Quarter 2020 on April 22 at 9.30 a.m. CET

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company's Interim Report for the period January - March 2020 on Wednesday, April 22,...

Mar 03, 2020, 02:11 ET Alzheimer Patients at Swedish Clinics to be Included in Phase 3 Study of Drug Candidate BAN2401

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company's partner Eisai will include Swedish clinics in the confirmatory...

Dec 17, 2019, 10:21 ET BioArctic Announces Research Collaboration with Eisai Regarding BAN2401

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today the initiation of a research collaboration with Eisai aimed at further studying the...

Dec 05, 2019, 14:35 ET BioArctic's Partner Eisai Presents Data from the Ongoing BAN2401 Phase 2b Extension Study in Early Alzheimer's Disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that data from the ongoing BAN2401 Phase 2b open-label extension study in early...

Dec 02, 2019, 02:17 ET BioArctic and Eisai to Present Data on BAN2401 at the Clinical Trials on Alzheimer's Disease Conference

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that presentations related to BAN2401 will be given at the 12th Clinical Trials on...

Nov 18, 2019, 18:17 ET BioArctic Announces Results From Interim Analysis of the Phase 1/2 Study of SC0806 in Patients With Complete Spinal Cord Injury

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today the results of an interim analysis of a Phase 1/2 study of SC0806 in patients with...

Jul 18, 2019, 01:13 ET BioArctic and Eisai Present New Data Regarding BAN2401 at the Alzheimer's Association International Conference 2019

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that new data related to BAN2401 were presented on July 17. The presentations were held by...

Jul 15, 2019, 11:14 ET BioArctic's Co-Founder Received AAIC Lifetime Achievement Award

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced that on Sunday, its co-founder, Lars Lannfelt, professor in geriatrics at Uppsala University ...